Study on Ciltacabtagene Autoleucel and Talquetamab for Treating High-Risk Multiple Myeloma

Inclusion Criteria

• Have a confirmed diagnosis of multiple myeloma (MM) that can be measured at the start of the study.
• For certain groups (Cohorts 1 and 3), have received at least three previous treatments for MM and completed at least one full cycle of treatment.
• For another group (Cohort 2), be newly diagnosed with MM and unable to have high-dose chemotherapy with a stem cell transplant.
• For Cohorts 1 and 3, show evidence that the disease has progressed or did not respond to the last treatment.
• Be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
• Women who can become pregnant must have a negative pregnancy test before starting the study.

Exclusion Criteria

• For Cohorts 1 and 3, have not received CAR-T cell therapy or any treatment targeting BCMA or GPRC5D before.
• For Cohort 2, have not received any treatment for MM or smoldering myeloma, except for a short course of steroids.
• For Cohorts 1 and 3, have not had an allogenic stem cell transplant within 6 months before starting the study or an autologous stem cell transplant within 12 weeks before starting the study.
• For Cohort 2, have not taken strong medications that affect liver enzymes within a certain period before starting specific induction therapy.
• Have not received a live vaccine within 4 weeks before joining the study.
• Have not fully recovered from side effects of previous cancer treatments, except for hair loss or mild nerve damage.